-
Mashup Score: 3
PURPOSE Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC). METHODS This open-label, multicenter study (ClinicalTrials.gov identifier: NCT03786081) included dose-escalation arms that assessed dose-limiting toxicities (DLTs) and identified the recommended phase II dose (RP2D) of TV in combination with bevacizumab (arm A), pembrolizumab (arm B), or carboplatin (arm C). The dose-expansion arms evaluated TV antitumor activity and safety at RP2D in combination with carboplatin as first-line (1L) treatment (arm D) or with pembrolizumab as 1L (arm E) or second-/third-line (2L/3L) treatment (arm F). The primary end point of dose expansion was objective response rate (ORR). RESULTS A total of 142 patients were enrolled. In dose escalation (n = 41), no DLTs were observ
Source: ascopubs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer - Eduardo Gonzalez-Ochoa, Ana C Veneziani, Amit M Oza, 2023 - 8 month(s) ago
Ovarian cancer is the second leading cause of death from gynecologic malignancies worldwide. Management of platinum-resistant disease is challenging and clinica…
Source: journals.sagepub.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0Designing and Using Antibody-Drug Conjugates to Treat Solid Tumors - 11 month(s) ago
How much do you know about antibody-drug conjugates (ADCs) for solid tumor management?
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Designing and Using Antibody-Drug Conjugates to Treat Solid Tumors - 11 month(s) ago
How much do you know about antibody-drug conjugates (ADCs) for solid tumor management?
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Designing and Using Antibody-Drug Conjugates to Treat Solid Tumors - 11 month(s) ago
How much do you know about antibody-drug conjugates (ADCs) for solid tumor management?
Source: MedscapeCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Antibody drug conjugates in brain tumors – new kids on the block? - 11 month(s) ago
A review on the intracranial activity of ADCs in primary and secondary brain tumors
Categories: General Medicine Journals and Societies, Latest HeadlinesTweet
-
Mashup Score: 0Antibody-Drug Conjugate Gets FDA Thumbs Up for Untreated DLBCL - 11 month(s) ago
Adding polatuzumab vedotin to a modified version of R-CHOP significantly improved PFS
Source: www.medpagetoday.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 1Blenrep for Multiple Myeloma Withdrawn From US Market - 1 year(s) ago
The manufacturer is pulling the drug from the market at the request of the FDA following disappointing results from a large phase 3 confirmatory trial.
Source: MedscapeCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1#108 - DESTINY-Breast04: Trastuzumab Deruxtecan em pacientes com câncer de mama avançado HER2 "Low" - 2 year(s) ago
Listen to this episode from Clinical Papers Podcast on Spotify. O DESTINY-Breast04 Ă© o primeiro RCT a benefĂcios clinicamente significativos para pacientes com câncer de mama metastático HER2 low.Como regra geral, pacientes com câncer de mama avançado e baixos nĂveis de expressĂŁo de HER2 (HER2 low) sĂŁo considerados como HER2-negativos porque as terapias direcionadas a HER2 geralmente se mostram…
Source: SpotifyCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 18Degrader-antibody conjugates - 2 year(s) ago
Degrader-antibody conjugates (DACs) are novel entities that combine a proteolysis targeting chimera (PROTAC) payload with a monoclonal antibody via some type of chemical linker. This review provides a current summary of the DAC field. Many general aspects associated with the creation and biological performan
Source: pubs.rsc.orgCategories: Hem/Oncs, Latest HeadlinesTweet
👀 Tisotumab vedotin combined with chemotherapy and #Immunotherapy shows encouraging activity in recurrent #CervicalCancer. 👉 https://t.co/OUrr6uLfFE #gyncsm #ADC #ImmunoOnc https://t.co/e4IARUGGRt